BGMS cyclacel.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Bio Green Med Solution Inc (BGMS) is developing advanced tumor-fighting methods, focusing on blocking the replication of malignant cells through a high-precision scientific approach. The stock's price history reflects the EV/EBITDA multiple, which currently stands at 0.00. Stable profits are driven by patents for cycle inhibitors and steady patient demand. Furthermore, the US jurisdiction and the absence of trade restrictions guarantee the protection of the business's intellectual property rights.

This indicator compares the total value of a company's assets and debt obligations against its operating profit before depreciation and amortization, allowing for an assessment of the business's real value excluding tax effects. For Bio Green Med Solution Inc (BGMS), the EV/EBITDA multiple adjusted for net debt is critical, as it determines capital stability during the development of costly oncology drugs and the monetization of patents.